Source - SMW
Biotechnology company Destiny Pharma said it had entered into a collaboration agreement with SporeGen to co-develop a preventive treatment for COVID-19.

Under the agreement, the parties would share any costs and commercial returns from the potential Covid-19 treatment and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months. 

The SPOR‑COV product consisted of a formulation of Bacillus bacteria that would be administered nasally as a spray.

Destiny Pharma and SporeGen were awarded a grant of £800,000 to fund the majority of the £1m cost of the initial SPOR-COV programme.








At 8:15am: (LON:DEST) Destiny Pharma Plc share price was +7.5p at 56.5p



Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.